All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How do CAR T-cell recipients respond to COVID-19 vaccination?

During the 4th European CAR T-Cell Meeting, the Multiple Myeloma Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv, IL. We asked, how do CAR T-cell recipients respond to COVID-19 vaccination

How do CAR T-cell recipients respond to COVID-19 vaccination?

In this video, Nagler discusses chimeric antigen receptor (CAR) T-cell therapy (CAR-T). He also highlights the challenges that COVID-19 has caused to CAR-T and the implications for patients with; Non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).



Subscribe to get the best content related to multiple myeloma delivered to your inbox